Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Cancer Janus Kinase Inhibitors Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Cancer Janus Kinase Inhibitors Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Ruxolitinib
      • 1.3.3 Momelotinib
      • 1.3.4 Lestaurtinib
      • 1.3.5 Pacritinib
    • 1.4 Market Segment by Application
      • 1.4.1 Global Cancer Janus Kinase Inhibitors Market Share by Application (2019-2025)
      • 1.4.2 Hospitals
      • 1.4.3 Ambulatory Surgical Centers
      • 1.4.4 Others
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Cancer Janus Kinase Inhibitors Market Size
      • 2.1.1 Global Cancer Janus Kinase Inhibitors Revenue 2014-2025
      • 2.1.2 Global Cancer Janus Kinase Inhibitors Sales 2014-2025
    • 2.2 Cancer Janus Kinase Inhibitors Growth Rate by Regions
      • 2.2.1 Global Cancer Janus Kinase Inhibitors Sales by Regions 2014-2019
      • 2.2.2 Global Cancer Janus Kinase Inhibitors Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Cancer Janus Kinase Inhibitors Sales by Manufacturers
      • 3.1.1 Cancer Janus Kinase Inhibitors Sales by Manufacturers 2014-2019
      • 3.1.2 Cancer Janus Kinase Inhibitors Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Cancer Janus Kinase Inhibitors Revenue by Manufacturers (2014-2019)
      • 3.2.2 Cancer Janus Kinase Inhibitors Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Cancer Janus Kinase Inhibitors Market Concentration Ratio (CR5 and HHI)
    • 3.3 Cancer Janus Kinase Inhibitors Price by Manufacturers
    • 3.4 Key Manufacturers Cancer Janus Kinase Inhibitors Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Cancer Janus Kinase Inhibitors Market
    • 3.6 Key Manufacturers Cancer Janus Kinase Inhibitors Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Ruxolitinib Sales and Revenue (2014-2019)
      • 4.1.2 Momelotinib Sales and Revenue (2014-2019)
      • 4.1.3 Lestaurtinib Sales and Revenue (2014-2019)
      • 4.1.4 Pacritinib Sales and Revenue (2014-2019)
    • 4.2 Global Cancer Janus Kinase Inhibitors Sales Market Share by Type
    • 4.3 Global Cancer Janus Kinase Inhibitors Revenue Market Share by Type
    • 4.4 Cancer Janus Kinase Inhibitors Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Cancer Janus Kinase Inhibitors Sales by Application

    6 United States

    • 6.1 United States Cancer Janus Kinase Inhibitors Breakdown Data by Company
    • 6.2 United States Cancer Janus Kinase Inhibitors Breakdown Data by Type
    • 6.3 United States Cancer Janus Kinase Inhibitors Breakdown Data by Application

    7 European Union

    • 7.1 European Union Cancer Janus Kinase Inhibitors Breakdown Data by Company
    • 7.2 European Union Cancer Janus Kinase Inhibitors Breakdown Data by Type
    • 7.3 European Union Cancer Janus Kinase Inhibitors Breakdown Data by Application

    8 China

    • 8.1 China Cancer Janus Kinase Inhibitors Breakdown Data by Company
    • 8.2 China Cancer Janus Kinase Inhibitors Breakdown Data by Type
    • 8.3 China Cancer Janus Kinase Inhibitors Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Cancer Janus Kinase Inhibitors Breakdown Data by Company
    • 9.2 Rest of World Cancer Janus Kinase Inhibitors Breakdown Data by Type
    • 9.3 Rest of World Cancer Janus Kinase Inhibitors Breakdown Data by Application
    • 9.4 Rest of World Cancer Janus Kinase Inhibitors Breakdown Data by Countries
      • 9.4.1 Rest of World Cancer Janus Kinase Inhibitors Sales by Countries
      • 9.4.2 Rest of World Cancer Janus Kinase Inhibitors Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Abbott Laboratories
      • 10.1.1 Abbott Laboratories Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Cancer Janus Kinase Inhibitors
      • 10.1.4 Cancer Janus Kinase Inhibitors Product Introduction
      • 10.1.5 Abbott Laboratories Recent Development
    • 10.2 Asana Biosciences
      • 10.2.1 Asana Biosciences Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Cancer Janus Kinase Inhibitors
      • 10.2.4 Cancer Janus Kinase Inhibitors Product Introduction
      • 10.2.5 Asana Biosciences Recent Development
    • 10.3 Astra Zeneca
      • 10.3.1 Astra Zeneca Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Cancer Janus Kinase Inhibitors
      • 10.3.4 Cancer Janus Kinase Inhibitors Product Introduction
      • 10.3.5 Astra Zeneca Recent Development
    • 10.4 Celon Pharmaceuticals
      • 10.4.1 Celon Pharmaceuticals Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Cancer Janus Kinase Inhibitors
      • 10.4.4 Cancer Janus Kinase Inhibitors Product Introduction
      • 10.4.5 Celon Pharmaceuticals Recent Development
    • 10.5 Dynamic Pharma
      • 10.5.1 Dynamic Pharma Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Cancer Janus Kinase Inhibitors
      • 10.5.4 Cancer Janus Kinase Inhibitors Product Introduction
      • 10.5.5 Dynamic Pharma Recent Development
    • 10.6 Eli Lilly
      • 10.6.1 Eli Lilly Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Cancer Janus Kinase Inhibitors
      • 10.6.4 Cancer Janus Kinase Inhibitors Product Introduction
      • 10.6.5 Eli Lilly Recent Development
    • 10.7 Gilead Sciences
      • 10.7.1 Gilead Sciences Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Cancer Janus Kinase Inhibitors
      • 10.7.4 Cancer Janus Kinase Inhibitors Product Introduction
      • 10.7.5 Gilead Sciences Recent Development
    • 10.8 Hanmi Pharmaceuticals
      • 10.8.1 Hanmi Pharmaceuticals Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Cancer Janus Kinase Inhibitors
      • 10.8.4 Cancer Janus Kinase Inhibitors Product Introduction
      • 10.8.5 Hanmi Pharmaceuticals Recent Development
    • 10.9 Incyte
      • 10.9.1 Incyte Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Cancer Janus Kinase Inhibitors
      • 10.9.4 Cancer Janus Kinase Inhibitors Product Introduction
      • 10.9.5 Incyte Recent Development
    • 10.10 Kyowa Hakko
      • 10.10.1 Kyowa Hakko Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Cancer Janus Kinase Inhibitors
      • 10.10.4 Cancer Janus Kinase Inhibitors Product Introduction
      • 10.10.5 Kyowa Hakko Recent Development
    • 10.11 Moleculin
    • 10.12 Pfizer
    • 10.13 PIQUR Therapeutics
    • 10.14 Portola Pharmaceuticals
    • 10.15 S-BIO

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Cancer Janus Kinase Inhibitors Sales Channels
      • 11.2.2 Cancer Janus Kinase Inhibitors Distributors
    • 11.3 Cancer Janus Kinase Inhibitors Customers

    12 Market Forecast

    • 12.1 Global Cancer Janus Kinase Inhibitors Sales and Revenue Forecast 2019-2025
    • 12.2 Global Cancer Janus Kinase Inhibitors Sales Forecast by Type
    • 12.3 Global Cancer Janus Kinase Inhibitors Sales Forecast by Application
    • 12.4 Cancer Janus Kinase Inhibitors Forecast by Regions
      • 12.4.1 Global Cancer Janus Kinase Inhibitors Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Cancer Janus Kinase Inhibitors Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Cancer Janus Kinase Inhibitors
      The conventional modes of cancer management including surgery, radiotherapy and chemotherapy were discarded as an aspirant for the future of cancer management long back ago. The arrival of modern cancer treatment modalities like immunotherapy and targeted therapy revolutionized the outlook of the future of cancer management. Amongst both of the modern therapies, targeted therapies have shown an impressive growth in a very short duration of time. The targeted therapies developed rapidly and gained much importance in the global market for cancer therapeutics due to their advantages over the conventional therapies. Targeted therapies are safer and more efficient approach for managing cancer. The only drawback for targeted therapies was that only a few targets were available for developing cancer therapeutics. The high efficacy of targeted therapeutics for cancer raised the demand for identifying new targets.
      In 2019, the market size of Cancer Janus Kinase Inhibitors is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Cancer Janus Kinase Inhibitors.

      This report studies the global market size of Cancer Janus Kinase Inhibitors, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Cancer Janus Kinase Inhibitors sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Abbott Laboratories
      Asana Biosciences
      Astra Zeneca
      Celon Pharmaceuticals
      Dynamic Pharma
      Eli Lilly
      Gilead Sciences
      Hanmi Pharmaceuticals
      Incyte
      Kyowa Hakko
      Moleculin
      Pfizer
      PIQUR Therapeutics
      Portola Pharmaceuticals
      S-BIO

      Market Segment by Product Type
      Ruxolitinib
      Momelotinib
      Lestaurtinib
      Pacritinib

      Market Segment by Application
      Hospitals
      Ambulatory Surgical Centers
      Others

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Cancer Janus Kinase Inhibitors status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Cancer Janus Kinase Inhibitors manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Cancer Janus Kinase Inhibitors are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now